PREDILIFE SA (ALPRE.PA) Stock Price, Forecast & Analysis
Europe - EPA:ALPRE - FR0010169920 - Common Stock
ALPRE.PA Key Statistics, Chart & Performance
The current stock price of ALPRE.PA is 3.03 EUR. In the past month the price decreased by -5.31%. In the past year, price decreased by -21.09%.
ALPRE.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 71.58 | 47.33B | ||
| 1AE.DE | ARGENX SE | 72.42 | 47.89B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 22.33B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.07B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.08B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.84B | ||
| 5CV.DE | CUREVAC NV | 5.3 | 1.04B | ||
| NANO.PA | NANOBIOTIX | N/A | 884.27M | ||
| PHIL.MI | PHILOGEN SPA | 20.61 | 687.14M | ||
| IVA.PA | INVENTIVA SA | N/A | 487.90M | ||
| FYB.DE | FORMYCON AG | N/A | 379.02M | ||
| VLA.PA | VALNEVA SE | N/A | 340.92M |
Related stock screener links
About ALPRE.PA
Company Profile
Predilife SA operates as a medical technology company. The company is headquartered in Villejuif, Ile-De-France and currently employs 20 full-time employees. The company went IPO on 2018-12-21. The firm operates mainly in the field of oncology. Predilife offers MammoRisk, which is a predictive breast cancer test that combines medical imaging thanks to a proprietary software, DenSeeMammo, Big Data and statistics through a scoring tool and genetic profiles via a polygenic risk score (PRS). The image is analysed in order to extract the breast density and the first breast cancer risk factor. In addition, The technology used by MammoRisk makes it possible to evaluate from a database of individuals tracked over time, the risks of an individual to develop cancer compared to the fate of his/her closest neighbors through a database of a number of American and French women.
Company Info
PREDILIFE SA
Igr Campus Cancer 1 Batiment Maurice, 39 Rue Camille Desmoulins
Villejuif ILE-DE-FRANCE FR
Employees: 19
Phone: 33142114211.0
PREDILIFE SA / ALPRE.PA FAQ
Can you describe the business of PREDILIFE SA?
Predilife SA operates as a medical technology company. The company is headquartered in Villejuif, Ile-De-France and currently employs 20 full-time employees. The company went IPO on 2018-12-21. The firm operates mainly in the field of oncology. Predilife offers MammoRisk, which is a predictive breast cancer test that combines medical imaging thanks to a proprietary software, DenSeeMammo, Big Data and statistics through a scoring tool and genetic profiles via a polygenic risk score (PRS). The image is analysed in order to extract the breast density and the first breast cancer risk factor. In addition, The technology used by MammoRisk makes it possible to evaluate from a database of individuals tracked over time, the risks of an individual to develop cancer compared to the fate of his/her closest neighbors through a database of a number of American and French women.
What is the stock price of PREDILIFE SA today?
The current stock price of ALPRE.PA is 3.03 EUR. The price increased by 0.33% in the last trading session.
Does PREDILIFE SA pay dividends?
ALPRE.PA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ALPRE stock?
ALPRE.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about PREDILIFE SA (ALPRE.PA) stock?
9 analysts have analysed ALPRE.PA and the average price target is 21.34 EUR. This implies a price increase of 604.24% is expected in the next year compared to the current price of 3.03.
How is the valuation of PREDILIFE SA (ALPRE.PA) based on its PE ratio?
PREDILIFE SA (ALPRE.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.13).
Can you provide the ownership details for ALPRE stock?
You can find the ownership structure of PREDILIFE SA (ALPRE.PA) on the Ownership tab.
ALPRE.PA Technical Analysis
ALPRE.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALPRE.PA. ALPRE.PA may be in some trouble as it scores bad on both profitability and health.
ALPRE.PA Financial Highlights
Over the last trailing twelve months ALPRE.PA reported a non-GAAP Earnings per Share(EPS) of -1.13. The EPS increased by 0.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -174.52% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ALPRE.PA Forecast & Estimates
9 analysts have analysed ALPRE.PA and the average price target is 21.34 EUR. This implies a price increase of 604.24% is expected in the next year compared to the current price of 3.03.
For the next year, analysts expect an EPS growth of -10.83% and a revenue growth 50.7% for ALPRE.PA